Immunovant, Inc. (IMVT) Stock Score, Valuation & Financial Research

Immunovant, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IMVT

Immunovant, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 32.11. These figures are a research snapshot, not a buy or sell recommendation.

What Immunovant, Inc. does

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Company business and revenue

Research reporting period: 2026-03-31. A research update is not a new financial filing.

How the company makes money

Immunovant is a clinical-stage immunology company that does not currently generate product revenue. Its business model focuses on the research and development of novel, targeted therapies for patients with autoimmune diseases, with the goal of commercializing these candidates following regulatory approval.

Products and services

  • The company is developing a pipeline of product candidates, including batoclimab and IMVT-1402, which are designed to treat various autoimmune conditions by targeting the neonatal fragment crystallizable receptor (FcRn).

Brands and product families

  • batoclimab — First-generation anti-FcRn antibody candidate. Source
  • IMVT-1402 — Next-generation anti-FcRn antibody candidate. Source

Customer types

Patients with autoimmune diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract research organizations and contract manufacturing organizations for clinical trial management, drug substance manufacturing, and supply chain services. Source

Competitors and product-market comparisons

  • Companies developing FcRn inhibitors — The company faces competition from other entities developing FcRn inhibitors for the treatment of autoimmune diseases. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting FcRn Source

Business risks and research considerations

  • History of operating losses and no product revenue Source
  • Dependence on regulatory approval for commercialization Source
  • Reliance on third-party manufacturers and clinical trial providers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IMVT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 32.11
Market capitalization:
6.63B (currency not supplied)
Revenue:
USD 7.1M
Net income:
USD -538.22M
Free cash flow:
USD -407.32M
Cash:
USD 797.8M
Total debt:
USD 72K
EPS:
USD -2.82

What stands out

  • Free cash flow is USD -407.32M, negative for the stored period.
  • The balance sheet shows USD 797.8M of cash versus USD 72K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -5740.9% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -7585.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 797.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IMVT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can IMVT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IMVT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IMVT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IMVT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research IMVT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.